Peerview Heart Lung & Blood Cme/cne/cpe Audio Podcast
John C. Byrd, MD - BTK Inhibition as an Anti-Cancer Strategy: Exploring a Model for Modern Targeted Therapy in Hematologic Malignancies and Beyond
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 1:10:01
- More information
Informações:
Synopsis
Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanism